Polysubstance Use Disorder: What It Is, Why It Is More Dangerous, and How Treatment Works

Most people who seek help for addiction are not managing a single substance. They are managing two, three, or more, each with its own withdrawal pattern, its own psychological pull, and its own complications in treatment. Polysubstance use disorder is the clinical term for this reality: the presence of more than one substance use disorder at the same time, whether the substances are used together or at different points in the day.

This guide covers what polysubstance use disorder is, which combinations carry the greatest risk, why it makes detox considerably more complex, and what an integrated treatment approach looks like in a residential setting.

What Is Polysubstance Use Disorder?

Polysubstance use disorder describes a pattern in which a person meets diagnostic criteria for a substance use disorder with more than one substance. The latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) does not list it as a single category. Instead, a clinician makes separate diagnoses for each substance involved, for example alcohol use disorder alongside opioid use disorder, once the criteria are met for each independently.

This matters because the old model, where people were sometimes assessed against a single primary substance, does not capture how most people with serious addiction actually present. According to research published in Frontiers in Psychiatry, drug-dependent individuals report using an average of 3.5 substances. The single-substance lens misses much of the clinical picture.

Polysubstance use can be simultaneous (two or more substances taken at the same time or close together) or sequential (different substances used at different points during the day or week). Both patterns create significant health risks and both complicate treatment.

How Common Is Polysubstance Use?

The scale of polysubstance use is larger than most people expect. The same Frontiers in Psychiatry review found that among people with substance use disorders, 11.3% have concurrent alcohol and illicit drug use disorders. That figure rises considerably when prescription medications are included.

Data compiled by the Agency for Healthcare Research and Quality (AHRQ) illustrates how frequently substances overlap in practice:

These are not rare edge cases. In clinical settings, they are the norm.

In terms of the human cost, the AHRQ data shows that nearly 50% of overdose deaths recorded in 2019 involved multiple drugs. Polysubstance use is not a complicating factor in the overdose crisis. For a very large proportion of people, it is the central one.

The Most Dangerous Combinations

Not all polysubstance combinations carry equal risk. The most dangerous involve central nervous system (CNS) depressants combined with one another, because their effects do not simply add together. They compound in ways that can shut down breathing.

Opioids and benzodiazepines are one of the most studied and most lethal pairings. Both suppress the CNS independently. Together, the sedation and respiratory depression are substantially amplified. According to the National Institute on Drug Abuse (NIDA), in 2021 nearly 14% of opioid overdose deaths also involved benzodiazepines. A North Carolina study cited by NIDA found the overdose death rate among patients receiving both medications was approximately 10 times higher than among those receiving opioids alone. Both drug classes now carry FDA boxed warnings about the risks of combined use.

Alcohol and opioids present a similar picture. Data from a 2015 peer-reviewed analysis published in BMC Psychiatry found that 22.1% of opioid-related deaths involved concurrent alcohol use. Of over 438,000 opioid-related emergency department visits in that period, 18.5% involved alcohol.

Alcohol and benzodiazepines interact through the same GABA receptor pathway, meaning each intensifies the sedating effect of the other. The same BMC Psychiatry analysis found that 26.1% of benzodiazepine-related deaths involved concurrent alcohol, and 27.2% of benzodiazepine-related ED visits involved alcohol.

Stimulants and depressants (for example, cocaine with alcohol, or methamphetamine with opioids) present a different but equally serious risk. The stimulant can mask the sedation produced by the depressant, which means a person may take a fatally high dose of the depressant without recognising the warning signs their body would normally produce.

The unifying danger across all these pairings is that the body’s normal alarm systems, the signals of intoxication that ordinarily prompt a person to stop, no longer operate reliably. Overdose can occur at doses that would not be fatal if either substance were taken alone.

Why Polysubstance Use Develops

People rarely set out to develop dependencies on multiple substances. The pattern typically develops over time through a combination of factors.

The most clinically significant driver is self-medication. Many people use substances to manage symptoms of an underlying mental health condition: anxiety, depression, trauma, chronic pain, or insomnia. When one substance stops working reliably, or when its side effects need managing, a second substance is often added. A person using opioids for pain management may add alcohol to help them sleep. Someone using stimulants to cope with demanding work may use benzodiazepines to come down in the evenings.

There is also a pharmacological dimension. Prior substance use substantially raises the risk of developing additional dependencies. Research in Frontiers in Psychiatry found that individuals with cocaine use history face a 15-fold increased risk of heroin dependence, and those who have misused prescription drugs face a 40-fold increased risk. The brain’s reward circuitry is already altered in ways that increase vulnerability.

Genetics plays a role too. According to the NIDA Comorbidities Research Report, genetic factors are thought to account for approximately 40-60% of vulnerability to substance use disorders, though this represents an estimate based on heritability studies rather than a precise biological certainty. Shared brain circuits and early environmental stressors affect both addiction vulnerability and mental health risk.

The Mental Health Connection

Polysubstance use disorder and mental illness are deeply intertwined. The NIDA Comorbidities Research Report estimates that approximately half of all individuals who experience a mental illness during their lifetime will also experience a substance use disorder, and the relationship runs in both directions.

Around 1 in 4 individuals with serious mental illness has a co-occurring substance use disorder. The figure is even higher among people presenting to addiction services, because mental illness is often the unaddressed root that drove the substance use in the first place.

Three main pathways explain the overlap. First, shared risk factors: genetic vulnerability and early trauma affect both. Second, mental illness preceding substance use: people experiencing anxiety, depression, or PTSD may use substances to manage those symptoms, a pattern often described as self-medication. Third, substance use preceding or triggering mental illness: chronic use of stimulants, cannabis, or alcohol can alter brain chemistry in ways that destabilise mood, induce paranoia, or worsen existing conditions.

In a polysubstance context, this creates a clinical situation of considerable complexity. Treatment that addresses the substances without the mental health condition is addressing only part of the picture.

Why Polysubstance Use Makes Detox More Complex

Detoxification from a single substance involves managing one withdrawal timeline, one set of physical symptoms, and one pharmacological protocol. Detox from multiple substances compounds every one of these factors.

Each substance has its own withdrawal pattern. Alcohol withdrawal typically begins within six to twelve hours of the last drink and peaks around 24-72 hours. Benzodiazepine withdrawal can take days to begin and may extend over weeks when a long-acting compound is involved. Opioid withdrawal tends to peak between 36 and 72 hours for short-acting opioids and later for long-acting formulations. When a person is dependent on two or more of these simultaneously, the clinical team must manage overlapping timelines that interact with each other.

The most acute danger in polysubstance detox is seizure risk. Both alcohol withdrawal and benzodiazepine withdrawal carry a risk of potentially life-threatening seizures if the substance is stopped abruptly or reduced too quickly. A person dependent on both faces a compounded risk. This is why medically supervised detox in a residential setting, with 24-hour clinical monitoring, is the appropriate level of care for most people presenting with polysubstance dependence involving CNS depressants.

Attempting to detox from multiple substances without medical supervision is particularly dangerous in this context. The temptation to manage one withdrawal with another substance, for example using alcohol to ease benzodiazepine withdrawal, compounds both dependencies and risks. A clinical team sequences and manages the tapers according to each person’s specific pattern of use, general health, and risk profile.

There is also the psychological dimension of simultaneous withdrawal. Multiple physical withdrawal processes occurring together intensify discomfort, raise anxiety, and increase the risk of leaving treatment prematurely. Medical support for symptom management, combined with psychological support that addresses the distress, is the standard of care in residential detox.

If you or someone you care about is dependent on alcohol, benzodiazepines, or opioids, do not attempt to stop suddenly without medical guidance. Withdrawal from these substances can be life-threatening. Please speak to a doctor or contact a treatment team before making any changes.

Why Treatment Is More Challenging

Beyond detox, the treatment of polysubstance use disorder is more difficult across every metric than treating a single substance use disorder. Research in Frontiers in Psychiatry found that polysubstance users experience poorer treatment retention, higher rates of relapse, and a three-fold higher mortality rate compared with single-substance users.

Several factors drive this. Multiple cravings operate simultaneously or in sequence, often triggered by different environmental cues. Pharmacotherapy choices are more constrained, because medications that support recovery from one substance may interact with another or with the medications used to manage a co-occurring condition. And the psychological work required is greater, because each substance may be serving a different function in the person’s coping system.

The capacity gap in treatment services also matters. According to the NIDA Comorbidities Research Report, only approximately 18% of substance use treatment programmes have the capacity to serve people with dual diagnosis (a co-occurring mental health condition alongside a substance use disorder). That figure likely underestimates how many people with polysubstance use disorder require integrated mental health support. A programme that cannot address the underlying mental health drivers of multi-substance use is not treating the full clinical picture.

What Integrated Treatment Looks Like

The evidence consistently supports integrated treatment as the appropriate approach for polysubstance use disorder: addressing all substances being used, together with any co-occurring mental health conditions, at the same time and within the same programme rather than sequentially.

Sequential treatment, where alcohol use disorder is addressed first and then other substances are dealt with afterwards, is less effective because the untreated substances and conditions continue to drive craving and relapse throughout.

Effective integrated treatment for polysubstance use disorder typically includes:

• Medical assessment and detox: A full clinical picture of all substances in use, medical history, and co-occurring conditions, followed by medically supervised withdrawal management with appropriately sequenced tapering where needed.
• Cognitive Behavioural Therapy (CBT): Identifying the thoughts, emotions, and situations that drive use across all substances, and developing coping strategies.
• Dialectical Behaviour Therapy (DBT): Particularly relevant where emotional dysregulation drives self-medication. DBT builds distress tolerance, emotional regulation, and interpersonal effectiveness.
• Trauma-informed therapy: Including EMDR for people whose polysubstance use is rooted in PTSD or significant adverse life experiences.
• Motivational interviewing: Building and sustaining internal motivation for change across a complex picture.
• Psychiatric support: Ongoing review and, where clinically appropriate, medication to support mental health alongside addiction recovery.
• Aftercare planning: Relapse prevention specific to each substance, co-occurring condition management, and peer support.

The residential setting is particularly valuable for polysubstance use disorder precisely because it provides the time, structure, and clinical coverage that the complexity of this presentation requires. Outpatient settings rarely offer the intensity of support that overlapping withdrawal, multiple cravings, and co-occurring mental health conditions need.

Treating Polysubstance Use Disorder at The Orchid Recovery, Chiang Mai

The Orchid Recovery is a boutique residential addiction and mental health programme in the Hang Dong District of Chiang Mai, Thailand, providing personalised care for a maximum of 20 international clients at any one time. We accept clients presenting with multiple substance use disorders and are experienced in the clinical complexity that polysubstance presentations bring.

Medical oversight is provided by Dr. Suttipan Takkapaijit, our CEO and full-time on-site psychiatrist (MD, Thai medical license 13333), supported by a nearby partnership with Chiang Mai Ram Hospital for any medical care that requires hospitalisation. The full-time on-site psychiatric presence means the medical picture is reviewed continuously throughout your stay, not at intervals. For clients who require it, our drug detox programme in Thailand provides structured medical detoxification before moving into the residential phase.

Our residential programme runs across four, eight, or twelve weeks. The therapeutic approach for polysubstance presentations draws on CBT and DBT for addiction and emotional regulation, EMDR and trauma therapy for clients whose use is rooted in unresolved traumatic experiences (delivered by Yuri Cardozo, our EMDRIA Level 3 credentialled trauma specialist), motivational interviewing, and group therapy. Psychiatric review runs throughout. Holistic activities, including yoga, Thai massage, mindfulness, and sound baths, are integrated into the weekly timetable as tools for nervous-system regulation, not optional extras.

Two months of complimentary aftercare is included with every residential programme. For people managing multiple substances and the underlying conditions that drove them, the transition back to everyday life requires sustained support. Our aftercare combines virtual follow-up with an on-site reunion where possible.

The distance that Thailand offers from the triggers, social network, and pressures of everyday life at home is itself a therapeutic variable. Removing yourself from the environment that sustained the pattern of use creates space for genuine change. For many of our clients who arrive managing multiple substances, that geographical separation is where the shift begins.

Not sure where to start? Managing more than one substance is something we work with every day Our small admissions team in Chiang Mai can walk you through what assessment and treatment would look like for your specific situation, with no pressure and no commitment required. Everything you share is confidential. Speak to our admissions team: /contact-us/

Sources

1. National Institute on Drug Abuse (NIDA). “Benzodiazepines and Opioids.” https://nida.nih.gov/research-topics/opioids/benzodiazepines-opioids
2. Sussman S, Lisha N, Griffiths M. “Prevalence of the Addictions: A Problem of the Majority or the Minority?” — Frontiers in Psychiatry. PMC7309369. https://pmc.ncbi.nlm.nih.gov/articles/PMC7309369/
3. Dasgupta N, Funk MJ, Proescholdbell S, et al. “Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality.” — Polysubstance Abuse: Alcohol, Opioids and Benzodiazepines. BMC Psychiatry. PMC4307731. https://pmc.ncbi.nlm.nih.gov/articles/PMC4307731/
4. Agency for Healthcare Research and Quality (AHRQ) Integration Academy. “Polysubstance Use & Integrated Behavioral Health.” https://integrationacademy.ahrq.gov/products/topic-briefs/polysubstance-use
5. National Institute on Drug Abuse (NIDA). “Common Comorbidities with Substance Use Disorders Research Report.” NCBI Bookshelf NBK571451. https://www.ncbi.nlm.nih.gov/books/NBK571451/
6. Cleveland Clinic. “Polysubstance Use Disorder: What It Is, Symptoms & Treatment.” https://my.clevelandclinic.org/health/diseases/polysubstance-abuse